Neuroblastoma Recurrent Clinical Trial
Official title:
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor in Combination With Irinotecan and Temozolomide in Patients With High-Risk Neuroblastoma With Primary Refractory Disease or in First Relapse. An International, Single-Arm, Multicenter Phase 2 Trial.
An International, Single-Arm, Multicenter Phase 2 Trial.
This is an international, single-arm, multicenter phase 2 trial, in patients ≥ 12 months of age with high-risk NB with primary refractory disease or in first relapse. Patients will receive naxitamab + GM-CSF + irinotecan/temozolomide. The Follow-Up period ends 2 years after End of Treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03242603 -
Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04903899 -
177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
|
Phase 2 | |
| Completed |
NCT02139397 -
Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04239092 -
9-ING-41 in Pediatric Patients With Refractory Malignancies.
|
Phase 1 | |
| Not yet recruiting |
NCT06465199 -
Difluoromethylornithine (DFMO) and AMXT-1501 for Neuroblastoma, CNS Tumors, and Sarcomas
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03373097 -
Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05754684 -
Quadruple Immunotherapy for Neuroblastoma
|
Phase 2 | |
| Completed |
NCT01467986 -
Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma
|
Phase 2 | |
| Completed |
NCT02258815 -
CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma
|
Phase 2 |